NCT06170671 - REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania | Biotech Hunter

Enrollment

250

Participants

Timeline

Start Date

December 13, 2023

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

Non interventional study

CLL patients routinely initiated on acalabrutinib by their physician between January 2023 -December 2024. Retrospective secondary data collection

Trial Locations (19)

20125

Research Site, Bucharest

22328

Research Site, Bucharest

30171

Research Site, Bucharest

50098

Research Site, Bucharest

110084

Research Site, Piteşti

200143

Research Site, Craiova

300239

Research Site, Timișoara

300254

Research Site, Timișoara

301710

Research Site, Bucharest

330084

Research Site, Deva

400015

Research Site, Cluj-Napoca

410469

Research Site, Oradea

430031

Research Site, Baia Mare

500052

Research Site, Brasov

540136

Research Site, Târgu Mureş

610136

Research Site, Piatra Neamţ

620034

Research Site, Focşani

700483

Research Site, Iași

800578

Research Site, Galati